KineMed licenses GeneGo’s MetaCore for Phase II leukemia study
KineMed’s kinetic biomarker of chronic lymphocytic leukemia flux as a predictor of disease course is intended to stratify indolent (simmering) versus aggressive disease. GeneGo’s genetic pathway database aligns
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.